US growth journey: boosting the Boyds brand stateside
To meet growing demand for our expertise and services in the US, Boyds established a physical presence stateside in 2021, recruiting US regulatory and program management professionals to our team. As we head into 2025, we take a look back at Boyds’ US growth journey to date.
By its very nature, drug development is a global market, and Boyds has always worked with international clients including in the US. The US is a thriving market for medicines development, where a wealth of funding opportunities and key biotech hubs drive innovation in the sector.
We knew there was untapped potential for Boyds to support even more US-based companies with the development of their medicinal products, which could only be achieved by us physically entering the market with a presence on the ground. This would enable us to further develop and maintain strong working relationships with the FDA for the benefit of our clients, including those outside of the US.
Therefore, in 2021, with the support of external advisers, we launched our strategic plan to expedite international growth. This led to the establishment of our US office in King of Prussia, West Philadelphia that year, known as ‘Cellicon Valley’ – a lynchpin hub for cell and gene therapy in the US. As well as boasting a rich heritage, the location provides a link between different time zones from Europe to the West Coast.
Going for growth
Anticipating strong growth, Boyds recruited staff in the US to support the office set-up, lead US business development, and bolster our US regulatory capabilities. In addition, Boyds obtained FDA agent status meaning we no longer need to work through a third-party agent in the US.
We then expanded our service offering with the launch of an in-house regulatory operations service, in response to evolving sector trends and growing demand from US clients. To support this, we recruited a dedicated, experienced regulatory operations team and invested in FDA-approved publishing software. The service enables Boyds to support the full lifecycle of our client’s drug development projects, from the initiation of scientific advice through to medicinal product filing and approval.
In addition, in support of our global growth, we successfully launched a number of new services including our interim chief medical officer offering, a start-up/investor readiness service, and pharmaceutical due diligence support.
To further embed ourselves in the US market, Boyds became a member of US life sciences sector bodies including MassBio, LSPA and BioNTx. Last year, we were also delighted to form a partnership with BioPharma Connections – a San-Francisco-based biopharmaceutical consulting company that provides strategic business development support to life sciences companies.
Future gazing: stars, stripes, and supporting success!
The US is a strategically important market for Boyds, and the industry as a whole, and we will continue to work with a growing number of US biotechs seeking our specialist drug development support and expertise. During 2025 and beyond, we look forward to growing our presence in the US, as well as forming new partnerships and connections, and helping more biotechs and pharma companies around the world – from Sydney to San Francisco – bring their medicines to market.
Boyds’ team of experts provides a wide range of expertise and skills central to the development of pharmaceutical and biotechnology medicinal products and medical devices. If you would like to talk to a member of our team about a specific project or area of expertise, please get in touch here.
